Oral interferon-α treatment of mice with cryoglobulinemic glomerulonephritis

American Journal of Kidney Diseases

Volumn 39, Issue 4, 2002, Pages 876-888

  Segerer, Stephan ^a   Hudkins, Kelly L ^a   Taneda, Sekiko ^a   Wen, Min ^a   Cui, Yan ^a   Segerer, Manuela ^a   Farr, Andrew G ^a   Alpers, Charles E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cryoglobulins; Interferon (IFN ); Membranoproliferative glomerulonephritis (MPGN); Thymic stromal lymphopoietin (TSLP)

Indexed keywords

ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COMORBIDITY; CONTROLLED STUDY; CRYOGLOBULINEMIA; DRUG EFFECT; HEPATITIS C; INGESTION; MACROPHAGE ACTIVATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PERIODIC ACID SCHIFF STAIN; RISK BENEFIT ANALYSIS; TRANSGENIC MOUSE;

EID: 0036200175     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.32011     Document Type: Article

References (34)

1. Cryoglobulins and cryoglobulinemia: Diagnostic and therapeutic considerations
2. Mixed cryoglobulinemia: New concepts
3. Biologic and clinical significance of cryoglobulins: A report of 86 cases
4. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis
5. Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients
6. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C
7. Cryoglobulinemic vasculitis
8. Cryoglobulinemic glomerulonephritis: A membranoproliferative glomerulonephritis induced by hepatitis C virus
9. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells
10. Molecular cloning and biological characterization of a novel murine lymphoid growth factor
11. Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice
12. Current treatment strategies for chronic hepatitis B and C
13. Interferon alpha in the treatment of polycythemia vera
14. Interferon-alpha therapy for melanoma
15. Therapy for cryoglobulinemia secondary to hepatitis C virus: The need for tailored protocols and multiclinic studies
16. Hepatitis C virus-associated glomerulonephritis: Effect of alpha-interferon therapy
17. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
18. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action
19. Oral use of interferon-alpha delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice
20. Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice
21. Oromucosal interferon therapy: Marked antiviral and antitumor activity
22. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy
23. Expression of chemokines and chemokine receptors during human renal transplant rejection
24. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis
25. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice
26. Anti-CD45RA antibodies increase the proliferation of mouse T cells to phytohemagglutinin through the interleukin 2/interleukin 2 receptor pathway
27. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis
28. Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial
29. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study
30. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon
31. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia
32. Thymic stromal lymphopoietin: A cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism
33. Impairment of T and B cell development by treatment with a type I interferon
34. Thl and Th2 T helper cell subsets affect patterns of iniury injury and outcomes in glomerulonephritis